173 related articles for article (PubMed ID: 9182979)
1. Inhibition of rat prostate carcinogenesis by a 5alpha-reductase inhibitor, FK143.
Homma Y; Kaneko M; Kondo Y; Kawabe K; Kakizoe T
J Natl Cancer Inst; 1997 Jun; 89(11):803-7. PubMed ID: 9182979
[TBL] [Abstract][Full Text] [Related]
2. Preventive effect of FK143, a 5alpha-reductase inhibitor, on chemical hepatocarcinogenesis in rats.
Maruyama S; Nagasue N; Dhar DK; Yamanoi A; El-Assal ON; Satoh K; Okita K
Clin Cancer Res; 2001 Jul; 7(7):2096-104. PubMed ID: 11448929
[TBL] [Abstract][Full Text] [Related]
3. FK143, a novel nonsteroidal inhibitor of steroid 5 alpha-reductase: (2) In vivo effects on rat and dog prostates.
Hirosumi J; Nakayama O; Chida N; Inami M; Fagan T; Sawada K; Shigematsu S; Kojo H; Notsu Y; Okuhara M
J Steroid Biochem Mol Biol; 1995 Apr; 52(4):365-73. PubMed ID: 7734405
[TBL] [Abstract][Full Text] [Related]
4. FK143, a novel nonsteroidal inhibitor of steroid 5 alpha-reductase: (1) In vitro effects on human and animal prostatic enzymes.
Hirosumi J; Nakayama O; Fagan T; Sawada K; Chida N; Inami M; Takahashi S; Kojo H; Notsu Y; Okuhara M
J Steroid Biochem Mol Biol; 1995 Apr; 52(4):357-63. PubMed ID: 7734404
[TBL] [Abstract][Full Text] [Related]
5. Effects of a new non-steroidal 5 alpha-reductase inhibitor, FK143, on the prostate gland in beagle dogs.
Inami M; Kawamura I; Naoe Y; Tsujimoto S; Mizota T; Manda T; Shimomura K
Jpn J Pharmacol; 1997 Jun; 74(2):187-94. PubMed ID: 9243327
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and pharmacodynamic study of a new nonsteroidal 5 alpha-reductase inhibitor, 4-[3-[3-[Bis(4-isobutylphenyl)methylamino]benzoyl]-1H-indol-1-yl]-butyr ic acid, in rats.
Katashima M; Yamamoto K; Tokuma Y; Hata T; Sawada Y; Iga T
J Pharmacol Exp Ther; 1998 Mar; 284(3):914-20. PubMed ID: 9495849
[TBL] [Abstract][Full Text] [Related]
7. CGP 53153: a new potent inhibitor of 5alpha-reductase.
Häusler A; Allegrini PR; Biollaz M; Batzl C; Scheidegger E; Bhatnagar AS
J Steroid Biochem Mol Biol; 1996 Feb; 57(3-4):187-95. PubMed ID: 8645628
[TBL] [Abstract][Full Text] [Related]
8. Effects of some novel inhibitors of C17,20-lyase and 5alpha-reductase in vitro and in vivo and their potential role in the treatment of prostate cancer.
Nnane IP; Kato K; Liu Y; Lu Q; Wang X; Ling YZ; Brodie A
Cancer Res; 1998 Sep; 58(17):3826-32. PubMed ID: 9731491
[TBL] [Abstract][Full Text] [Related]
9. Tissue distribution kinetics of a new nonsteroidal 5 alpha-reductase [correction of 5 A-reductase] inhibitor, 4-[3-[3-[bis(4-isobutylphenyl)methylamino]benzoyl]-1H-indol-1-YL ]-butyric acid, in rats.
Katashima M; Yamamoto K; Haraguchi K; Tokuma Y; Hata T; Sawada Y; Iga T
Drug Metab Dispos; 1997 Sep; 25(9):1051-8. PubMed ID: 9311620
[TBL] [Abstract][Full Text] [Related]
10. Novel steroid 5 alpha-reductase inhibitor FK143: its dual inhibition against the two isozymes and its effect on transcription of the isozyme genes.
Kojo H; Nakayama O; Hirosumi J; Chida N; Notsu Y; Okuhara M
Mol Pharmacol; 1995 Sep; 48(3):401-6. PubMed ID: 7565619
[TBL] [Abstract][Full Text] [Related]
11. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapeutic prevention studies of prostate cancer.
Djavan B; Zlotta A; Schulman C; Teillac P; Iversen P; Boccon Gibod L; Bartsch G; Marberger M
J Urol; 2004 Feb; 171(2 Pt 2):S10-3; discussion S13-4. PubMed ID: 14713746
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of FK143, a nonsteroidal inhibitor of steroid 5 alpha-reductase, in healthy volunteers.
Katashima M; Irino T; Shimojo F; Kawamura A; Kageyama H; Higashi N; Miyao Y; Tokuma Y; Hata T; Yamamoto K; Sawada Y; Iga T
Clin Pharmacol Ther; 1998 Mar; 63(3):354-66. PubMed ID: 9542479
[TBL] [Abstract][Full Text] [Related]
14. NTP Toxicology and Carcinogenesis Studies of C.I. Direct Blue 218 (CAS No. 28407-37-6) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1994 Feb; 430():1-280. PubMed ID: 12616301
[TBL] [Abstract][Full Text] [Related]
15. NTP Toxicology and Carcinogenesis Studies of 4,4'-Thiobis(6- t -butyl- m -cresol) (CAS No. 96-69-5) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1994 Dec; 435():1-288. PubMed ID: 12595928
[TBL] [Abstract][Full Text] [Related]
16. Androgen-induced regrowth in the castrated rat ventral prostate: role of 5alpha-reductase.
Wright AS; Douglas RC; Thomas LN; Lazier CB; Rittmaster RS
Endocrinology; 1999 Oct; 140(10):4509-15. PubMed ID: 10499505
[TBL] [Abstract][Full Text] [Related]
17. Actions of 5alpha-reductase inhibitors on the epididymis.
Robaire B; Henderson NA
Mol Cell Endocrinol; 2006 May; 250(1-2):190-5. PubMed ID: 16476520
[TBL] [Abstract][Full Text] [Related]
18. Effects of competitive and noncompetitive 5α-reductase inhibitors on serum and intra-prostatic androgens in beagle dogs.
Zhao XF; Yang Y; Wang W; Qiu Z; Zhang P; Wang B
Chin Med J (Engl); 2013 Feb; 126(4):711-5. PubMed ID: 23422194
[TBL] [Abstract][Full Text] [Related]
19. Region-specific expression of androgen and growth factor pathway genes in the rat epididymis and the effects of dual 5alpha-reductase inhibition.
Henderson NA; Cooke GM; Robaire B
J Endocrinol; 2006 Sep; 190(3):779-91. PubMed ID: 17003279
[TBL] [Abstract][Full Text] [Related]
20. [Chemoprevention of prostate cancer].
Djavan B; Thompson I; Michel MS; Waldert M; Seitz C
Urologe A; 2004 May; 43(5):557-61. PubMed ID: 15042290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
